UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2021 

Commission File Number: 001-31995

 

MEDICURE INC.

(Translation of registrant's name into English)

 

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

 

 

 

   
 

 


 

EXHIBIT LIST

Exhibit Title
   
99.1 News Release dated February 4, 2021 - Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021

 

 

 

 

   
 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Medicure Inc.
  (Registrant)
   
     
Date: February 4, 2021 By: /s/ Dr. Albert D. Friesen                           
  Dr. Albert D. Friesen
  Title: CEO

 

 



Exhibit 99.1

 

 

 

Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021

WINNIPEG, MB, Feb. 4, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC:MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 8, 2021 at 2:00 PM EST (1:00 PM CST, 12:00 PM MST). Medicure welcomes stakeholders, investors, and other individual followers to register and attend this live event.

The presentation will feature Albert Friesen, Chief Executive Officer & Chairman of the Board. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Company's website (www.medicure.com).

REGISTER HERE: https://talk-deck.com/info/live-register/?297!ut9dx30v1dy 

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley"), a pharmacy located in North Carolina that offers an Extended Supply mail order drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit http://www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email marleydrug@bellsouth.net. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, refer to the full Prescribing Information. For additional information about ZYPITAMAG®, refer to the full Prescribing Information.

About Renmark Financial Communications Inc.

Founded in 1999, Renmark Financial Communications Inc. is North America's leading retail investor relations firm.  Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly-traded clientele to maximize their visibility within the financial community and strengthen their investor audience.

View original content:http://www.prnewswire.com/news-releases/medicure-to-participate-in-renmarks-virtual-non-deal-roadshow-series-on-monday-february-8-2021-301222718.html

SOURCE Medicure Inc.

View original content: http://www.newswire.ca/en/releases/archive/February2021/04/c6697.html

%CIK: 0001133519

For further information: Renmark Financial Communications Inc., Account Manager: email@renmarkfinancial.com, Tel.: (416) 644-2020 or (212) 812-7680, www.renmarkfinancial.com

CO: Medicure Inc.

CNW 17:30e 04-FEB-21



This regulatory filing also includes additional resources:
ex991.pdf